Bavarian Nordic CEO receives "extraordinary" retention bonus
The Covid-19 pandemic has created high demand for executives with vaccine experience, and Bavarian Nordic has chosen to protect its President and CEO Paul Chaplin from poaching attempts by putting some cash aside to keep him in the fold.
BY RITZAU, TRANSLATED BY DANIEL PEDERSEN
Bavarian Nordic, which is developing a Covid-19 vaccine, has given its CEO Paul Chaplin a grant of millions of kroner to keep him in the company.
All of Medtech firm Ambu’s products already live up to the new EU rules for medical devices, something the firm attributes to a good sense of how much effort living up to the new legislation would require.
Expres2ion CEO Bent U. Frandsen is one of 3,000 volunteers participating in a phase III trial of Bavarian Nordic’s Covid-19 booster candidate. If the vaccine reaches the market, Expres2ion will be entitled to royalties.